Twist Bioscience: Betting on Liquid Biopsy Adoption and AI-Driven NGS Growth
Twist Bioscience looks positioned to ride accelerating demand for next-generation sequencing (NGS) and liquid biopsy applications — especially minimal residual disease (MRD) testing — while efficiency gains have started to show in GAAP results. The balance of high valuation and improving fundamentals creates an opportunistic, risk-managed long trad…